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ABSTRACT 
Objective: Demonstrating therapeutic equivalency regarding the efficacy and safety among originator products and generics is a key step in 
permitting the marketing of generic products. The study aimed to evaluate the bioequivalence of five different generic brands of Glimepiride tablets 
under biowaiver conditions. 
Methods: The quality of the tablet products, including uniformity of weight, friability, and disintegration test, was assessed using the United State 
Pharmacopeia (USP) general monograph for the tablet dosage form. The content of glimepiride in the tablets was measured using UV 
spectrophotometer at the wavelength 229 nm. The release of Glimepiride from the tested and originator tablet products was evaluated using the 
dissolution profiles conducted in HCI buffer pH 1.2, and phosphate buffer pH 6.4 and 7.8 by USP dissolution apparatus II. The bioequivalence of 
test products was assessed using the similarity and difference factors.  
Results:The tested products complied to USP requirements for quality standards; all the products show rapid disintegration, 
D1 show higher time (Three minutes) while D3 show lower time (28 seconds). The content of test products was (104.68, 93.75, 97.21, 97.03, and 
102.10) for D1, D2, D3, D4, and D5 , respectively, compare to 103.70 for OB. Dissolution profiles revealed that the highest similarity to the originator 
was showed in pH 6.4; f2 ranged (74.5-68.4) for all the tested products and low similarity in pH 7.8; f2 ranged (45.2-64.7). 
Conclusion: The study showed that the generic products has noticeable similarity with the originator brand and it can be interchangeable. 
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INTRODUCTION 
Demonstrating therapeutic equivalency regarding the efficacy and 
safety among innovator and generic products is a key step in 
permitting the marketing of generic products [1, 2]. Bioavailability 
studies directed in animals and/or humans are considered as time 
and money consuming steps in the developing of a new 
pharmaceutical product [1, 3]. Using of dissolution tests can be 
considered as a substitute for in vivo bioavailability studies. It is a 
cheaper, easier, and less time-consuming test, consequently, it is 
used as substitute to in vivo studies [4, 5]. Generic products are 
varying in their bioavailability due to variation in manufacturing 
processing condition, type of formulation and techniques used; 
moreover, they must be equivalence to the innovator, so the 
regulatory authority required in vivo bioavailability study to ensure 
the equivalence of generic products [1-3] but these studies are 
expensive and take a long time, in order tominimize the number and 
type of bioequivalence studies that have to be carried out. The World 
Health Organization (WHO), International Council for 
Harmonization (ICH), and Food and Drug Administration (FDA) 
suggest wavier of in vivo bioequivalence studies using in vitro 
release dissolution data for immediate release oral solid dosage 
form based on Biopharmaceutical Classification System (BCS) [1, 6-
11]. BCS is based on waiving bioequivalence studies depending on 
the solubility and gastrointestinal permeability of drug substance 
and it use for generic products development by manufacturer as it 
save time and resources [1] For registration of generic products it is 
required that a bioequivalence study must be provided to indicate 
generic products are equivalence to originator one that must be with 
same active ingredient, same dosage forms, and strength, in order to 
submit for marketing authorization[12]. Biowaiver studies are 
conducted to evaluate the therapeutic equivalence of two or more 
products alternative to the in vivo testing [13-16]. In addition, to 
determine the conditions required for the dissolution test [17, 18]. 
Glimepiride is an oral sulfonylurea agent for the treatment of type 2 
diabetes mellitus it causes a decrease in blood glucose by inducing 
insulin secretion from β cells in the pancreas and by increasing 
peripheral tissue sensitivity to insulin [19]. Glimepiride available as 
an oral dosage form and completely absorbed from GIT After 
administration [20]. The peak plasma concentrations (Cmax) will 
reach in 2 to 3 h; it possess highly plasma protein-bound (PPB) 
approximately 99.5% [21], It has a half-life around 5 to 8 h, which 
may increase with multiple doses up to 9 h; hence these factors 
contribute to an inconsistent profile of dissolution and absorption, 
and hence variations in bio-availability and drug action [22, 23]. The 
biopharmaceutical characteristic of Glimepiride is described as low 
solubility in aqueous media and high permeability in gastrointestinal 
tracts. The drug shows low, pH-dependent solubility. So, based on 
studied biopharmaceutical data, Glimepiride could be classified into 
BCS Class II [24]. According to WHO, biowaiver procedure eligible in 
Class II [highly permeable and poorly soluble] when rapidly 
dissolving (release of>85% of the labeled amount of drug in 30 min), 
[25]. Glimepiride displays pH-dependent solubility. The drug is 
extremely poorly soluble in acid and neutral media. On the other 
hand, the solubility of drugs is slightly raised to (0.02) mg/ml in 
alkali media with pH>7 [26].  
The study aimed to evaluate the bioequivalence of five different 
generic brands of Glimepiride 3 mg tablets under biowaiver 
conditions, in vitro dissolution test were conducted for five generic 
products of Glimepiride immediate-release tablet in the market 
mentioned as D1, D2, D3, D4 and D5 in comparison to Originator 
brand [Amaryl® 3 mg] in three different pH media HCl buffer pH 1.2 
and phosphate buffer pH 6.4 and 7.8. 
MATERIALS AND METHODS 
Materials 
Reference Glimepiride was a kind gift sample from (Tabouk Co., 
KSA). Four generic brands of Glimepiride 3 mg tablets market in KSA 
named D1, D2, D3, and D4 and the Originator brand (OB) Amaryl®3 
mg [Sanofi S. p. An Italy] was purchased from a registered pharmacy. 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058  Vol13, Issue 1, 2021 
Gaberet al. 
Int J App Pharm, Vol 13, Issue 1, 2021, 187-192 
188 
Hydrochloric acid (LobaChemiePvt. Ltd, India), potassium chloride 
(Avonchem limited, UK), potassium dihydrogen orthophosphate 
(LobaChemiePvt. Ltd, India), sodium hydroxide (May and Baker LTD, 
Bahenham, England) Potassium Chloride (AVONCHEM limited), 
methanol (Sigma-Aldrich, USA). 
Characterization of physiochemical parameters  
Physiochemical properties of the tablet products, including 
uniformity of weight, friability, disintegration test, and drug content, 
were assessed according to United State Pharmacopeia (USP) 
standard for the official test and to the manufacture specification to 
non-official tests [27]. 
Preparation of different buffer media 
The buffer media used in the study are HCl buffer pH 1.2 and phosphate 
buffer pH 6.4 and 7.8 were prepared according to USP [27]. 
Ultraviolet scanning of glimepiride in different pH buffer media 
Stock solutions of glimepiride in methanol were prepared and serial 
dilution was made using the three previously mentioned buffer media. 
The spectrum of these solutions was run using a spectrophotometer at 
200-400 nm to determine the maximum absorption wavelength (λ max). 
The precision of the method was verified by inter-day and intra-day 
variation studies. 
Preparation of standard calibration curves 
A concentration ranged between 2-20 μg/ml of Glimepiride standard 
was prepared from stock solutions using methanol and the buffer 
system, using Ultra-violet spectrophotometric method at the 
predetermined maximum wavelength, the absorption of these 
solutions were measured and lines of regression were plotted. The 
calibration made in methanol was used for content determination 
while that in HCl buffer pH1.2 and phosphate buffer pH 6.4 and 7.8 
were used for the dissolution studies of the sample tablets. 
Drug content assay 
Ten tablets from each brand were randomly selected and weighted 
to obtain the average. The tablets were crushed to powder using 
mortar and pestle, an exact quantity of the powder equivalent to 10 
mg glimepiride was weighed and transferred to a 100 ml volumetric 
dissolve using methanol, the solution was sonicated for 10 min and 
the volume was completed to 100 ml with methanol, the resulting 
solution was filtered using Whatman filter paper, 5 ml of the filtrate 
was transferred to 50 ml volumetric flask and diluted with methanol 
to 50 ml, a concentration of 0.001% w/v of glimepiride was 
obtained. The resulting solution was measured at 229 nm using 
UV/visible spectrophotometer and the percentage content of each 
product was calculated using the calibration standard curve. The 
experiment was performed in triplicate for each brand; mean values 
and standard deviation were calculated [28].  
Dissolution study 
The dissolution was carried out using 900 ml of three different 
buffer media; HCl buffer pH 1.2, phosphate buffer pH 6.4 and 
phosphate buffer pH 7.8, using an eight-station USP dissolution 
apparatus II (VK 7020 Vankel®, Canada) and the temperature was 
maintained at 37 °C±0.5 and 75 rpm.  
Five-milliliter samples were collected at predetermined time 
intervals 5, 10, 15, 30, 45 and 60 min. Five ml of fresh medium pre-
warmed to 37 °C was replaced into dissolution medium after each 
sampling to maintain sink condition requirements. All samples were 
filtered using Whatman filter paper and were measured using a 
UV/Vis spectrophotometer at 229 nm. The percentage release was 
calculated at each time interval. The experiment was carried out in 
triplicate, and the mean values were obtained. The results were 
declared as the percentage of the cumulative amount of drug 
released versus time [29]. 
Analysis of data 
Simple statistics measurement (mean±standard deviation) was used 
to analyze data of weight variation, diameter, thickness, friability, 
drug content, and disintegration. The dissolution profile differences 
were assessed based on the similarity factor (f2) and the difference 
factor (f1) as:  
f2 = 50 ∗ log{[1 + �
1
n
��(Rt − Tt)2] − 0.5 ∗ 100} 
f2; similarity factor and Rt and Tt are percents dissolved at each time 
point for reference and test products, respectively. f2 Values of 50 or 
higher (50-100) confirm the similarity of the products. 
f1 = [� | Rt − Tt|/�Rt] ∗ 100 
f1 value of 0 to 15 confirms a slight difference between the two 
products[7, 30]. 
RESULTS AND DISCUSSION 
Physical characteristics evaluation 
Five generic brands D1, D2, D3, D4 and D5 of Glimepiride 3 mg 
immediate-release tablets were studied in comparison to the 
Originator Brand (OB). The quality test conducted was; tablet weight 
variation, friability, and disintegration, all products comply with the 
pharmacopeial standards of tablet dosage forms. The uniformity of 
weight test was conducted to ensure the uniformity of weight, which 
reveal the content uniformity also the test indicates the appropriate 
size of tablets [31]. All tested tablets showed a percentage weight 
variation within the range of±7.5% and thus it meets the USP 
Pharmacopeia standards specification of weight variation and the 
quality control test [32]. Friability test is conducted to assess the 
capability of the tablet to withstand mechanical stress during 
manufacturing, packaging and transportation, which lead to physical 
defect in tablets like capping, chipping, abrasion and breaking. 
Therefore, it is essential for tablets to withstand such stress. The 
USP stated that the loss of weight due to friability should be less 
than 1%, all the test products were within this standard. D3 and D5 
showed the lowest loss in weight (0.09% and 0.11) respectively 
followed by D1 and D4 (0.12 and 0.14) respectively; which revealed 
their capability to withstand mechanical stress. Tablets 
disintegration is the break down of tablet to small particles and it is 
one of the most important indications of dissolution and hence 
bioavailability of products [33, 34]. The disintegration time of all 
tested products are within a specified time of less than 15 min for 
uncoated tablets, which will be influenced on the dissolution. All the 
generic and originator products disintegrate in time less than 1 minute 
to 3 min, with highest disintegration time obtained by generic D1 
(3:00 min); which will revealed in better release (table 1). 
 
Table 1: Physical characteristics evaluation of selected generic brands of tablets in comparison to originator brand [OB] 










D1 Pink, Oblong with break 2.627±0.32 5.53±0.06 157.35±1.22 0.12 3:00±0.36 
D2 Of white, Oblong with Break 3.133±0.02 5.19±0.03  166.15±1.32 0.36 0:28±0.83 
D3 Of white, Oblong with Break 4.208±0.01 5.48±0.04 148.5±0.73 0.09 2:11±0.31 
D4 Of white, Oblong with Break 4.478±0.01 5.62±.06  223.9±1.72 0.14 2:18±0.11 
D5 Of white, Oblong with Break 3.128±0.011 6.53±0.048  172.9±1.89 0.11 0:37±0.10 
OB Of white, Oblong with Break 2.32±0.025 5.7±0.32 166.35±1.15 0.24 1:.24±0.07 
* Results expressed as mean±SD, ** n= number of sample  
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Spectrum of glimepiride in different pH media 
Spectrums scan for Glimepiride standard solution in three different 
pH mediums 1.2, 6.4, and 7.8 were performed in a range between 
200-400 nm. It showed a maximum wavelength absorption (λmax) at 
229 nm for all media as shown in fig. 1. 
Calibration curve for glimepiride in the three buffer media 
Glimepiride standard solution in the HCl buffer system pH 1.2 and 
phosphate buffer pH 6.4 and 7.8 show linearity in the concentration 
range 2-20 µg/ml as detected by linearity equation and regression as 
shown in fig. 2. 
 
 
Fig.1: UV spectrum scan for glimepiride standard in pH 6.8 medium 
 
 




Fig. 3: Drug content of glimepiride tablets, *results expressed as mean±SD, sample size= 3 
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Drug content assay 
The content uniformity results are shown in fig. 2. All tablet samples 
were complying with pharmacopeial limits, i.e. the percentage 
average drug content of all samples were (104.68, 93.75, 97.21, 
97.03, and 102.10) for D1, D2, D3, D4, and D5, respectively compare 
to 103.70 for OB. All results within the USP standard range of 90% to 
110% of the label statement amount. 
Dissolution studies 
In vitro dissolution profiles comparison was conducted to ensure 
quality equivalence and approval of generic formulations in HCl 
buffer pH 1.2 and phosphate buffer pH 6.4 and 7.8. Compared to the 
reference product, the dissolution profile and percent release in 60 
min for each tablet in the three buffer system is shown in fig. 3-5. 
The similarity factor f2 and difference factor f1 are calculated in the 
three buffer system in comparison with the originator brand. 
In the hydrochloric acid buffer media pH 1.2 all generic brands D1, 
D2, D3, D4, and D5 met originator requirement with similarity factor 
60.0, 55, 57.67, 60.64 and 59.93, respectively. The difference factors 
were 4.69, 6.81, 4.14, 3.97 and 3.09 respectively in addition all the 
products release more than 85% of the active ingredient in 15 min, 
so they passed the WHO requirement of rapidly dissolving and met 
the biowaiver criteria. 
In contrast, the release of the drug in phosphate buffer pH 6.4 
revealed that all products meet the WHO requirements. As the 
similarity factor of all products more than 50 (74.5, 74.0, 68.5, 66.4 
and 68.5 respectively) and the f1 values are less than 15 for all 
products. The release of the active pharmaceutical ingredient from 
OB, D1,D2,D3, D4, and D5 in phosphate buffer pH 6.4 and 7.8 is more 
than 85% in 15 min which indicates the fulfillment of WHO 
biowaiver criteria however the similarity factor of D1; in phosphate 
buffer pH7.8 is less than 50 and for the other products about 50 
which revealed poor bioequivalence of D1 generic drugs compare to 
the originator in contrast to D5 show high similarity factor which 
may be due to the type of excipient and manufacturing process. 
From the results of dissolution profile in this study it observable that 
the generic drugs is mostly similar to the originator one in all buffer 
media specially phosphate buffer pH 6.4, and it released more than 
85% of API in 15 min and crossed similarity factor in all pH medium 
so it can be considered as bioequivalent with the OB under 
experiment conditions. The dissolution profiles of different products 
under investigation did not show correlation between the strength 
and dissolution of tablets. ANOVA test results showed that different 
tablets had different strengths (p<0. 01). OB and D2, which had 
different strength values (fig. 3), had more than 85% of the drug 
released within 15 min, which revealed the finding that not only 
content of drugs and the manufacturing conditions, affect drug 
release but also formula factors, such as disintegrates and diluents 
types play an important part in the disintegration of tablet and 
dissolution profiles.Based on biowaiver study results, D1 sample in pH 
7.8 is not bioequivalent with the OB unless further an in vivo 
bioequivalent studies prove that as it comparable to Reddy, N. H., et al., 
finding that some but not all Acyclovir, Atenolol, and Ciprofloxacin 
Hydrochloride products met the biowaiver criteria [35]. Excipients 
and additives used in manufacturing tablets have great effects on their 
dissolution, therefore to achieve biowaiver according to regulatory 
rules, good manufacturing practice should be followed and careful 
selection of the excipients used is mandatory. 
 
 
Fig. 4: Dissolution profiles of OB, D1, D2, D3, D4 and D5 tablets at pH 1.2 dissolution medium (n=3, mean±SD) 
 
 
Fig. 5: Dissolution profiles of OB, D1, D2, D3, D4 and D5 tablets at pH 6.4 dissolution medium (n=3, mean±SD) 
Gaberet al. 
Int J App Pharm, Vol 13, Issue 1, 2021, 187-192 
191 
 
Fig. 6: Dissolution profiles of OB, D1, D2, D3, D4 and D5 tablets at pH 7.8 dissolution medium (n=3, mean±SD) 
 
CONCLUSION 
The regulatory authority is controlling the marketed drug products 
to prevent the substandard drug from market to safe patients from 
harmful substandard one and from therapeutics failure. The selected 
Glimepiride tablet generic products available in Saudi market show 
high quality and in comparable to the originator Amaryl, that 
revealed the strength of regulatory authority and quality control in 
KSA In order to decrease the cost of the health care system generic 
drugs are widely market, however they must be equivalence to 
originator to assure bioavailability. Biowaiver is an alternative to the 
costly bioequivalence study of generic drugs to the originator drug. 
The in vitro dissolution profile in our study showed that all generic 
brand has noticeable similarity with the originator brand and it can 
be interchangeable with it. Excipients and manufacturing process 
play an important role in equivalence of generic drug products to 
originator and to fulfil the biowaiver criteria. 
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